APOBEC3G — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL170289	0.40	6/20
SCHEMBL14751	0.84	3/20
Trigonelline (SCHEMBL195666)	0.53	3/20
SCHEMBL67836	0.50	3/20
SCHEMBL34097	1.00	2/20
SCHEMBL50688	0.62	2/20
SCHEMBL51046	0.62	2/20
SCHEMBL160108	0.58	2/20
SCHEMBL64694	0.58	2/20
SCHEMBL140214	0.57	2/20
SCHEMBL140215	0.57	2/20
Octenidine (SCHEMBL124821)	0.56	2/20
SCHEMBL50008	0.55	2/20
Octenidine (SCHEMBL126065)	0.54	2/20
Octenidine (SCHEMBL126751)	0.54	2/20
SCHEMBL90967	0.54	2/20
Chloroneb (SCHEMBL22739)	0.54	2/20
Pentolinium (SCHEMBL210048)	0.53	2/20
Trigonellamide (SCHEMBL132244)	0.53	2/20
SCHEMBL1051	0.52	2/20

Clinical trials — most relevant to APOBEC3G by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
EFFICACY AND SAFETY OF A SIMPLIFICATION STRATEGY BASED ON DOLUTEGRAVIR AND DARUNAVIR / COBICISTAT VS OPTIMIZED TREATMENT IN SUPPRESSED HIV-1-INFECTED PATIENTS CARRYING ARCHIVED MULTIDRUG RESISTANCE MUTATIONS	PHASE4	COMPLETED
Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B Mutation	PHASE2	ACTIVE_NOT_RECRUITING
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Gene Therapy for ADA-SCID	PHASE1/PHASE2	COMPLETED
Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer	PHASE2	RECRUITING
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies	PHASE1/PHASE2	RECRUITING
Phase II Prospective Cohort Study of Intravesical Recombinant Human Type 5 Adenovirus Injection for Treatment of High-Risk Non-Muscle Invasive Bladder Cancer: Evaluating Efficacy and Safety	PHASE2	NOT_YET_RECRUITING
Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency	PHASE1	COMPLETED
Treatment of SCID Due to ADA Deficiency With Autologous Transplantation of Cord Blood or Hematopoietic CD 34+ Cells After Addition of a Normal Human ADA cDNA by the EFS-ADA Lentiviral Vector	PHASE1	COMPLETED
Breast Cancer Neoantigen Vaccination With Autologous Dendritic Cells	PHASE1	COMPLETED
Redirected MazF-CD4 Autologous T Cells for HIV Gene Therapy	PHASE1	COMPLETED
A Phase 1 Safety and Dose Finding Study of GLIX1 in Adults With Recurrent or Progressive High-grade Glioma	PHASE1	RECRUITING
CS-121 APOC3 Base Editing in Children and Adolescents With Hyperchylomicronemia	EARLY_PHASE1	RECRUITING
Role of Viral Reservoir, Immune Activation and Depletion in Persistent Viremia Persistent Viremia in People Living With HIV on Antiretroviral Therapy	nan	NOT_YET_RECRUITING
Investigation of ADA Enzyme Deficiency	nan	UNKNOWN
Observational Study Evaluating the Prevalence of Enzyme Deficiency in Pulmonology Clinics (ADA)	nan	UNKNOWN
COsegregation of VARiants in Panel of Genes	nan	RECRUITING
Epitranscriptomic Blood Biomarkers for Coronary Artery Disease - A Prospective Cohort Study (IHD-EPITRAN)	nan	UNKNOWN
Gene Therapy for ADA-SCID Using an Improved Lentiviral Vector (Ivlv-ADA)	nan	RECRUITING
Expression of TET1 Gene in Acute Leukaemia	nan	UNKNOWN
ADAR1 Expression Level in Rectal Cancer	nan	RECRUITING
Natural History of Autosomal Dominant Hearing Loss	nan	RECRUITING
Dolutegravir-based Dual Therapies in HIV-infected Patients With Virological Suppression	nan	COMPLETED
Endocrine Disruptors and Life STILe in Breast Cancer Development	nan	UNKNOWN
A Dose-escalation Trial of Stereotactic Ablative Body Radiotherapy for Non-spine Bone & Lymph Node Oligometastates	nan	COMPLETED
The Natural History of Severe Viral Infections and Characterization of Immune Defects in Patients Without Known Immunocompromise	nan	RECRUITING
Characterisation of the Immune Response to SARS-CoV-2 Infection / COVID-19 in Type 1 Diabetes	nan	COMPLETED
Cervical Thermal Ablation to Treat Persistent HPV Infection	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a APOBEC3G binder may also engage these)

Protein	Name	Similarity
Q694C1	—	1.000	Q694C1 →
Q694B6	—	1.000	Q694B6 →
Q7YR24	—	1.000	Q7YR24 →
Q7YR23	—	1.000	Q7YR23 →
Q7YR25	—	1.000	Q7YR25 →
Q694C0	—	1.000	Q694C0 →
Q694C4	—	1.000	Q694C4 →
Q694C5	—	1.000	Q694C5 →
Q694B9	—	1.000	Q694B9 →
Q694C2	—	1.000	Q694C2 →
Q694B8	—	1.000	Q694B8 →
Q694B7	—	0.998	Q694B7 →
APOBEC3B	DNA dC->dU-editing enzyme APOBEC-3B	0.997	landscape →
Q4VDN5	—	0.995	Q4VDN5 →
Q694B5	—	0.995	Q694B5 →
Q8IUX4	—	0.994	Q8IUX4 →
Q1WBT4	—	0.993	Q1WBT4 →
Q96AK3	—	0.992	Q96AK3 →
P60705	—	0.991	P60705 →
Q9GZX7	—	0.991	Q9GZX7 →
Q99J72	—	0.990	Q99J72 →
P60704	—	0.990	P60704 →
Q6NTF7	—	0.990	Q6NTF7 →
Q75W64	—	0.990	Q75W64 →
APOBEC3A	DNA dC->dU-editing enzyme APOBEC-3A	0.987	landscape →
APOBEC3C	DNA dC->dU-editing enzyme APOBEC-3C	0.985	landscape →
Q2PT36	—	0.982	Q2PT36 →
Q19Q52	—	0.981	Q19Q52 →
Q9WVE0	—	0.980	Q9WVE0 →
A9QA56	—	0.978	A9QA56 →